All In Biotech

Drug Trial Radar · NCT06293365

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 155 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

155

Actual

Start

Jul 2, 2024

Primary completion

Feb 17, 2026

Study completion Jan 16, 2029

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL auto-injector (AI) versus two injections of 150 mg/1 mL pre-filled syringe (PFS), and to evaluate the safety and tolerability of ianalumab following the s.c. administration of both devices in participants with rheumatoid arthritis (RA), Sjögren's disease (SjD), or systemic lupus erythematosus (SLE). A second cohort will be included with the objective of demonstrating the comparability of pharmacokinetics of ianalumab between 1 x 2 mL Pre-filled Syringe (PFS) and 2 x 1 mL PFS.

Conditions

  • Sjögrens Disease
  • Systemic Lupus Erythematosus
  • Rheumatoid Arthritis

Interventions

  • VAY736 1ml PFSBiological

    Solution for injection.

  • VAY736 2 ml PFSBiological

    Solution for injection

  • VAY736 2ml AIBiological

    Solution for injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Area under the curve (AUC) calculated to the end of a dosing interval (tau) at steady-state (AUCtau) for ianalumabTime frame: Over a dosing interval after 3rd (between Week 8 and 12) and 6th dose (between Week 20 and 24).
  2. Cohort 1: Maximum (peak) observed serum drug concentration after dose administration (Cmax) for ianalumabTime frame: Over a dosing interval after 3rd (between Week 8 and 12) and 6th dose (between Week 20 and 24).
  3. Cohort 2: Area under the curve (AUC) calculated to the end of a dosing interval (tau) at steady-state (AUCtau) for ianalumabTime frame: Over a dosing interval after 3rd (between Week 8 and 12) and 6th dose (between Week 20 and 24).
  4. Cohort 2: Maximum (peak) observed serum drug concentration after dose administration (Cmax) for ianalumabTime frame: Over a dosing interval after 3rd (between Week 8 and 12) and 6th dose (between Week 20 and 24).

Locations

37 sites in 8 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group Llc

    Anniston, Alabama

  • Providence Medical Foundation

    Fullerton, California

  • Advanced Medical Research

    La Palma, California

  • Conquest Research

    Winter Park, Florida

  • Parris and Associates Rheumatology

    Lawrenceville, Georgia

  • Indiana Univ School of Dentistry

    Indianapolis, Indiana

  • Ochsner Health System

    Baton Rouge, Louisiana

  • Ahmed Arif Medical Research Center

    Grand Blanc, Michigan

  • Paramount Med Rsrch and Consult LLC

    Middleburg Heights, Ohio

  • RAO Research LLC

    Oklahoma City, Oklahoma

  • Altoona Center for Clin Res

    Duncansville, Pennsylvania

  • West Tennessee Research Institute

    Jackson, Tennessee

  • Shelby Research LLC

    Memphis, Tennessee

  • Novel Research LLC

    Bellaire, Texas

  • Southwest Rheum Rsrch LLC

    Mesquite, Texas

  • Uni of Texas Health Science Center

    San Antonio, Texas

  • Advanced Rheumatology of Houston

    The Woodlands, Texas

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Quilmes, Buenos Aires, Argentina

  • Novartis Investigative Site

    San Miguel Tucuman, Tucumán Province, Argentina

  • Novartis Investigative Site

    Hamilton, Ontario, Canada

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Rimouski, Quebec, Canada

  • Novartis Investigative Site

    Trois-Rivières, Quebec, Canada

  • Novartis Investigative Site

    Brno, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Uherské Hradiště, Czechia

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, Hungary

  • Novartis Investigative Site

    Salerno, SA, Italy

  • Novartis Investigative Site

    Krakow, Poland

  • Novartis Investigative Site

    Lublin, Poland

  • Novartis Investigative Site

    A Coruña, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Santiago Compostela, A Coruna, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.